{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:34:30Z","timestamp":1791588870816,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40265-022-01741-z","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T06:07:32Z","timestamp":1657778852000},"page":"1143-1150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Nemolizumab: First Approval"],"prefix":"10.1007","volume":"82","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"issue":"8","key":"1741_CR1","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMe1916733","volume":"382","author":"SG Kwatra","year":"2020","unstructured":"Kwatra SG. Breaking the itch-scratch cycle in prurigo nodularis. N Engl J Med. 2020;382(8):757\u20138.","journal-title":"N Engl J Med"},{"key":"1741_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-3-030-55617-4_8","volume":"1290","author":"AH Rook","year":"2021","unstructured":"Rook AH, Rook KA, Lewis DJ. Interleukin-31, a potent pruritus-inducing cytokine and its role in inflammatory disease and in the tumor microenvironment. Adv Exp Med Biol. 2021;1290:111\u201327.","journal-title":"Adv Exp Med Biol"},{"key":"1741_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.639097","volume":"8","author":"JM Nemmer","year":"2021","unstructured":"Nemmer JM, Kuchner M, Datsi A, et al. Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. Front Med (Lausanne). 2021;8:639097. https:\/\/doi.org\/10.3389\/fmed.2021.639097","journal-title":"Front Med (Lausanne)."},{"key":"1741_CR4","doi-asserted-by":"publisher","unstructured":"Furue M, Furue M. Interleukin-31 and pruritic skin. J Clin Med. 2021;10(9):1906. https:\/\/doi.org\/10.3390\/jcm10091906.","DOI":"10.3390\/jcm10091906"},{"issue":"8","key":"1741_CR5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s10157-021-02047-2","volume":"25","author":"E Kinugasa","year":"2021","unstructured":"Kinugasa E, Igawa K, Shimada H, et al. Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study. Clin Exp Nephrol. 2021;25(8):875\u201384.","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"1741_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40521-018-0191-3","volume":"5","author":"T Nakahara","year":"2018","unstructured":"Nakahara T, Furue M. Nemolizumab and atopic dermatitis: the interaction between interleukin-31 and interleukin-31 receptor as a potential therapeutic target for pruritus in patients with atopic dermatitis. Curr Treat Opt Allergy. 2018;5(4):405\u201314.","journal-title":"Curr Treat Opt Allergy."},{"issue":"4","key":"1741_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/exd.13533","volume":"27","author":"C Nakashima","year":"2018","unstructured":"Nakashima C, Otsuka A, Kabashima K. Interleukin-31 and interleukin-31 receptor: new therapeutic targets for atopic dermatitis. Exp Dermatol. 2018;27(4):327\u201331.","journal-title":"Exp Dermatol"},{"issue":"1","key":"1741_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/exd.13236","volume":"27","author":"S Oyama","year":"2018","unstructured":"Oyama S, Kitamura H, Kuramochi T, et al. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody. Exp Dermatol. 2018;27(1):14\u201321.","journal-title":"Exp Dermatol"},{"issue":"7","key":"1741_CR9","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/ni1084","volume":"5","author":"SR Dillon","year":"2004","unstructured":"Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5(7):752\u201360.","journal-title":"Nat Immunol"},{"key":"1741_CR10","doi-asserted-by":"publisher","unstructured":"Kuzumi A, Yoshizaki A, Matsuda KM, et al. Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. Nat Commun. 2021;12:5947. https:\/\/doi.org\/10.1038\/s41467-021-26099-w.","DOI":"10.1038\/s41467-021-26099-w"},{"issue":"2","key":"1741_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","volume":"117","author":"E Sonkoly","year":"2006","unstructured":"Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1741_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.638325","volume":"8","author":"K Kabashima","year":"2021","unstructured":"Kabashima K, Irie H. Interleukin-31 as a clinical target for pruritus treatment. Front Med (Lausanne). 2021;8: 638325.","journal-title":"Front Med (Lausanne)."},{"issue":"3","key":"1741_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jdermsci.2014.02.009","volume":"74","author":"A Kato","year":"2014","unstructured":"Kato A, Fujii E, Watanabe T, et al. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis. J Dermatol Sci. 2014;74(3):229\u201335.","journal-title":"J Dermatol Sci"},{"issue":"9","key":"1741_CR14","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1093\/rheumatology\/keaa195","volume":"59","author":"B Yaseen","year":"2020","unstructured":"Yaseen B, Lopez H, Taki Z, et al. Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. Rheumatology (Oxford). 2020;59(9):2625\u201336.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1741_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40272-019-00342-w","volume":"21","author":"HL Nguyen","year":"2019","unstructured":"Nguyen HL, Anderson KR, Tollefson MM. New and emerging therapies for pediatric atopic dermatitis. Paediatr Drugs. 2019;21(4):239\u201360.","journal-title":"Paediatr Drugs"},{"key":"1741_CR16","unstructured":"Maruho. Chugai and Maruho announce license agreement of nemolizumab (CIM331), a novel biologic in the skin disease area for the Japanese market [media release]. 28 Sept 2016. http:\/\/www.maruho.co.jp."},{"key":"1741_CR17","unstructured":"Chugai Pharmaceutical. Chugai and Galderma announce global license agreement for nemolizumab (CIM331), novel biologic for skin diseases [media release]. 21 Jul 2016. http:\/\/www.chugai-pharm.co.jp."},{"key":"1741_CR18","unstructured":"Galderma. Galderma announces new data demonstrating the positive anti-inflammatory effect and mode of action of nemolizumab in patients with moderate to severe prurigo nodularis [media release]. 3 Dec 2021. http:\/\/www.galderma.com."},{"key":"1741_CR19","unstructured":"Maruho. Maruho acquires manufacturing and marketing approval in Japan for \"Mitchga\u00ae Subcutaneous Injection 60mg Syringes\", a new treatment targeting itch associated with atopic dermatitis [media release]. 28 Mar 2022. https:\/\/www.maruho.co.jp\/english\/information\/20220328.html."},{"key":"1741_CR20","unstructured":"Maruho. Nemolizumab (Mitchga\u00ae Syringes): Japanese prescribing information. 2022. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/730155_44904A4G1023_1_01. Accessed 20 Apr 2022."},{"issue":"4","key":"1741_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40259-021-00490-x","volume":"35","author":"N Yang","year":"2021","unstructured":"Yang N, Chen Z, Zhang X, et al. Novel targeted biological agents for the treatment of atopic dermatitis. BioDrugs. 2021;35(4):401\u201315.","journal-title":"BioDrugs"},{"issue":"3","key":"1741_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s13555-021-00678-7","volume":"12","author":"R Sidbury","year":"2022","unstructured":"Sidbury R, Alpizar S, Laquer V, et al. Pharmacokinetics, safety, efficacy, and biomarker profiles during nemolizumab treatment of atopic dermatitis in adolescents. Dermatol Ther (Heidelb). 2022;12(3):631\u201342.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"8","key":"1741_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","volume":"382","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020;382(8):706\u201316.","journal-title":"N Engl J Med"},{"issue":"4","key":"1741_CR24","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jaci.2021.10.004","volume":"149","author":"LC Tsoi","year":"2022","unstructured":"Tsoi LC, Hacini-Rachinel F, Fogel P, et al. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J Allergy Clin Immunol. 2022;149(4):1329\u201339.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1741_CR25","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/jcph.969","volume":"57","author":"T Saito","year":"2017","unstructured":"Saito T, Iida S, Terao K, et al. Dosage optimization of nemolizumab using population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling and simulation. J Clin Pharmacol. 2017;57(12):1564\u201372.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1741_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1917006","volume":"383","author":"K Kabashima","year":"2020","unstructured":"Kabashima K, Matsumura T, Komazaki H, et al. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020;383(2):141\u201350.","journal-title":"N Engl J Med"},{"issue":"4","key":"1741_CR27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.20873","volume":"186","author":"K Kabashima","year":"2022","unstructured":"Kabashima K, Matsumura T, Komazaki H, et al. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol. 2022;186(4):642\u201351.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1741_CR28","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1606490","volume":"376","author":"T Ruzicka","year":"2017","unstructured":"Ruzicka T, Hanifin JM, Furue M, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376(9):826\u201335.","journal-title":"N Engl J Med"},{"issue":"4","key":"1741_CR29","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","volume":"142","author":"K Kabashima","year":"2018","unstructured":"Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142(4):1121-30.e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1741_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","volume":"145","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Pinter A, Pulka G, et al. Phase 2b randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173\u201382.","journal-title":"J Allergy Clin Immunol"},{"key":"1741_CR31","doi-asserted-by":"crossref","unstructured":"St\u00e4nder S, Yosipovitch G, Lacour JP, et al. Nemolizumab is associated with a rapid reduction of itch and sleep disturbance in patients with prurigo nodularis [abstract no. 33307 plus poster]. In: American Academy of Dermatology Annual Meeting. 2022.","DOI":"10.1016\/j.jaad.2022.06.771"},{"key":"1741_CR32","unstructured":"Galderma. Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis. [media release]. 22 Jun 2022. http:\/\/www.galderma.com"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01741-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01741-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01741-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T10:29:46Z","timestamp":1676111386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01741-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1741"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01741-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"17 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}